Cargando…
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study
BACKGROUND: (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. Host genetic determinants of response are therefore in demand. METHODS: In this genome-wide association study (GWAS), CHB patients, treated with (Peg)IFN for at least 12 weeks...
Ejemplares similares
-
A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B
por: Geeratragool, Tanawat, et al.
Publicado: (2023) -
A Comparison of Clinical Manifestations and Outcomes between Acute Sporadic Hepatitis A and Hepatitis E Infections in Thailand
por: Khongviwatsathien, Sirajuk, et al.
Publicado: (2023) -
Validation of the prognostic models in acute-on-chronic liver failure precipitated by hepatic and extrahepatic insults
por: Maipang, Kotchakon, et al.
Publicado: (2019) -
Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B
por: Rugivarodom, Manus, et al.
Publicado: (2023) -
Hepatitis B Virus HBx Activates Notch Signaling via Delta-Like 4/Notch1 in Hepatocellular Carcinoma
por: Kongkavitoon, Pornrat, et al.
Publicado: (2016)